Article History
Accepted: 26 June 2023
First Online: 27 July 2023
Competing interests
: A.F. and S.M. are inventors on pending or issued patentsĀ (US10.183.038, US10.052.345) aimed at diagnosing or treating proteinuric kidney diseases and therefore stand to gain royalties from their future commercialization. A.F. is Chief Scientific Officer of L&F Health LLC, holds equity interests in L&F Research and is the inventor of assets developed by ZyVersa Therapeutics. ZyVersa has licensed worldwide rights to develop and commercialize hydroxypropyl-Ī²-cyclodextrin for the treatment of kidney disease from L&F Research. A.F. also holds equity in River 3 Renal Corporation. S.M. holds equity interest in L&F Research. A.M. declares no competing interests.